Overall Trading Platform
BioNTech SE is a biotechnology business based in the US. BioNTech shares (BNTX) are listed on the NASDAQ and all prices are listed in US Dollars. BioNTech employs 1,941 staff and has a trailing 12-month revenue of around USD$482.3 million.
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
Since the stock market crash in March caused by coronavirus, BioNTech's share price has had significant positive movement.
Its last market close was USD$102.6, which is 68.47% up on its pre-crash value of USD$32.35 and 266.43% up on the lowest point reached during the March crash when the shares fell as low as USD$28.
If you had bought USD$1,000 worth of BioNTech shares at the start of February 2020, those shares would have been worth USD$1,695.28 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$3,389.90.
|Latest market close||USD$102.6|
|52-week range||USD$46.3 - USD$213.15|
|50-day moving average||USD$149.9697|
|200-day moving average||USD$116.1544|
|Wall St. target price||USD$198.28|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.5631|
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-05-07)||N/A|
|1 month (2021-04-16)||-32.30%|
|3 months (2021-02-18)||-8.92%|
|6 months (2020-11-18)||13.45%|
|1 year (2020-05-18)||70.52%|
|2 years (2019-05-14)||N/A|
|3 years (2018-05-14)||N/A|
|5 years (2016-05-14)||N/A|
Valuing BioNTech stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of BioNTech's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
BioNTech's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.0476. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into BioNTech's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
|Revenue TTM||USD$482.3 million|
|Gross profit TTM||USD$-222,037,000|
|Return on assets TTM||-13.07%|
|Return on equity TTM||1.63%|
|Market capitalisation||USD$46.6 billion|
TTM: trailing 12 months
There are currently 3.8 million BioNTech shares held short by investors – that's known as BioNTech's "short interest". This figure is 19.2% down from 4.7 million last month.
There are a few different ways that this level of interest in shorting BioNTech shares can be evaluated.
BioNTech's "short interest ratio" (SIR) is the quantity of BioNTech shares currently shorted divided by the average quantity of BioNTech shares traded daily (recently around 2.8 million). BioNTech's SIR currently stands at 1.39. In other words for every 100,000 BioNTech shares traded daily on the market, roughly 1390 shares are currently held short.
However BioNTech's short interest can also be evaluated against the total number of BioNTech shares, or, against the total number of tradable BioNTech shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case BioNTech's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 BioNTech shares in existence, roughly 20 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable BioNTech shares, roughly 0 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against BioNTech.
Here’s what you need to know about travelling to South Africa from Singapore.
Here’s what you need to know when travelling to Mexico from Singapore.
Here’s everything we know so far about The Honest Company IPO and how to buy in from Singapore.
This is what you need to know about travelling to the USA from Singapore.
Here’s what you need to know about travelling to India from Singapore.
Find out what you need to know about heading to Greece from Singapore.
Who can travel, the quarantine and immunisation rules and everything else you need to travel to New Zealand from Singapore.
Find out what rules are in place for travel from Singapore to Fiji.
Discover the current rules on travelling to the UK from Singapore.
These are the rules to know if you’re thinking of travelling to the Bahamas from Singapore.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.